10-K: Quince Therapeutics Reports Fiscal Year 2024 Results, Focuses on eDSP Development for Rare Diseases

Quince Therapeutics details its 2024 activities, highlighting the Phase 3 NEAT trial for eDSP in A-T and strategic focus on rare disease treatments.

Summary

• Quince Therapeutics is a late-stage biotechnology company focusing on rare diseases, utilizing its AIDE technology platform.
• The company's lead asset, eDSP, is in a pivotal Phase 3 clinical trial for Ataxia-Telangiectasia (A-T), with 61 participants enrolled as of March 24, 2025.
• Topline results from the Phase 3 NEAT clinical trial are expected in the fourth quarter of 2025.
• Quince is also expanding its pipeline to include Duchenne Muscular Dystrophy (DMD) as a second development program.
• The company completed a patient sizing project estimating approximately 4,600 A-T patients in the U.S.
• Quince reported a net loss of $56.8 million for the year ended December 31, 2024, and has an accumulated deficit of $376.5 million.
• There is substantial doubt about the company's ability to continue as a going concern without raising additional funding.
• The company has potential milestone payments of up to $485 million to EryDel shareholders and additional remuneration payments to EIB based on eDSP commercialization.
• As of December 31, 2024, Quince had $40.8 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical pipeline, the financial situation raises concerns about the company's long-term viability. The high potential milestone payments also add financial pressure.

Positives

• eDSP has Fast Track designation from the FDA, potentially expediting its development and review.
• The company has a Scientific Advisory Board (SAB) to provide insights and advice.
• The AIDE technology platform has potential benefits over conventional therapies.
• The company has a strong senior leadership team with experience in drug development and commercialization.
• The company has completed the evaluation process of other potential rare disease indications for eDSP beyond A-T and DMD.

Negatives

• The company has a limited operating history and has never generated revenue from sales.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company is dependent on the success of eDSP, which has previously failed to meet its primary efficacy endpoint in the ATTeST trial.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms.
• The company has and may be required to make additional milestone payments to EryDel shareholders and additional remuneration payments to EIB.
• The company incurred a $17.1 million goodwill impairment charge in 2024.

Risks

• The Phase 3 NEAT clinical trial may not be successful and may not result in NDA approval.
• Clinical drug development is a lengthy, expensive, and uncertain process.
• The company's drug candidates may cause undesirable side effects.
• The company may not be able to successfully demonstrate a favorable differentiation between eDSP and currently available corticosteroids.
• The potential rare disease target patient populations of EryDex are small, and the addressable patient population even smaller.
• The terms of the EIB Loan place restrictions on the company's operating and financial flexibility.
• The company relies on third parties to conduct clinical trials and manufacture drug candidates, and those third parties may not perform satisfactorily.
• The company may fail to meet the requirements for continued listing on Nasdaq.

Future Outlook

The company plans to complete enrollment of the Phase 3 NEAT clinical trial by the end of the second quarter of 2025 and report topline results in the fourth quarter of 2025. They also plan to initiate a DMD Phase 2 clinical trial in 2025, pending additional funding, and prepare for NDA and MAA submissions in 2026, provided positive NEAT study results.

Management Comments

• The company benefits from a strong senior leadership team who possess a wide range of biotech expertise that encompasses all stages of drug development, regulatory submission and approval, and commercialization.
• The team has previously been involved in drug programs that resulted in numerous FDA approvals, founded and sold companies, and participated in various public and private financings that resulted in hundreds of millions of dollars of company investment, in addition to a number of successful exits that generated billions of dollars in shareholder value.
• The company believes this breadth of experience will meaningfully benefit the Company as we work to successfully execute our strategic priorities.

Industry Context

The company operates in the competitive biotechnology industry, facing competition from large and specialty pharmaceutical companies, academic research institutions, and others. There are currently no approved therapies for A-T, presenting an opportunity for eDSP to be the first treatment on the market, but it faces pipeline competition.

Comparison to Industry Standards

• IntraBio is developing Aqneursa (levacetylleucine) for A-T.
• Grace Therapeutics is developing GTX-102, an oral spray formulation of betamethasone, for A-T.
• Matrix Biomed is developing MBM-01, an EPAS1/HIF1 inhibitor, for A-T.
• Boston Childrens Hospital is developing a splice-switching antisense oligonucleotide for A-T.
• Ultragenyx markets triheptanoin under the name Dojolvi, which is in development by The University of Queensland for A-T.
• Oslo University Hospital is developing nicotinamide riboside for A-T.
• There are many available corticosteroids, including prednisone, prednisolone, betamethasone, deflazacort, vamorolone, and many in development that could allow for longer half-lives and less AEs than approved corticosteroids.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be affected by potential future reductions in force.
• Patients with A-T and DMD could benefit from successful development and approval of eDSP.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• Complete enrollment of Phase 3 NEAT clinical trial in the second quarter of 2025.
• Report Phase 3 NEAT clinical trial topline results in the fourth quarter of 2025.
• Initiate DMD Phase 2 clinical trial in 2025, pending additional funding.
• Prepare for U.S. NDA submission in 2026, provided positive NEAT study results.
• Prepare for European MAA submission in 2026, provided positive NEAT study results.
• Initiate a Pediatric Investigational Plan to evaluate a younger population of patients with A-T in 2025.
• Advance U.S. commercial planning activities for eDSP for A-T.
• Select one to two additional immunological and autoimmune focused rare disease indications for eDSP.
• Evaluate potential strategic partnerships to out-license ex-U.S. rights for eDSP.

Key Dates

Keywords

eDSP, Ataxia-Telangiectasia, AIDE technology, clinical trial, rare diseases, Quince Therapeutics, DMD, biotechnology, FDA, NEAT